200499
Bexarotene
A retinoid X receptor (RXR) agonist that can permeate the blood-brain barrier and rapidly reduce Aβ40 and Aβ42 levels in APP/PS1 mice in an ApoE-dependent manner.
동의어(들):
Bexarotene, 4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic acid
로그인조직 및 계약 가격 보기
모든 사진(2)
About This Item
실험식(Hill 표기법):
C24H28O2
CAS Number:
Molecular Weight:
348.48
MDL number:
UNSPSC 코드:
12352200
NACRES:
NA.77
추천 제품
Quality Level
분석
≥99% (HPLC)
형태
powder
제조업체/상표
Calbiochem®
저장 조건
OK to freeze
protect from light
색상
white
solubility
DMSO: 50 mg/mL, clear, colorless
배송 상태
ambient
저장 온도
−20°C
InChI
1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
InChI key
NAVMQTYZDKMPEU-UHFFFAOYSA-N
일반 설명
A retinoid X receptor (RXR) agonist that can permeate the blood-brain barrier and rapidly reduce Aβ40 and Aβ42 levels in APP/PS1 mice in an ApoE-dependent manner (25% reduction in 6 h and 50% reduction in 72 h). Causes a rapid reversal of cognitive, social, and olfactory deficts. Shown to progressively enhance the expression of ApoE and ATP-binding cassette transporters ABCA1 and ABCG1. Also stimulates the secretion of highly lapidated HDL particles in primary microglia and astrocytes. Does not affect the levels of Aβ proteases, insulin degrading enzyme, and neprilysin.
생화학적/생리학적 작용
Cell permeable: yes
Reversible: yes
포장
Packaged under inert gas
경고
Toxicity: Regulatory Review (Z)
재구성
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
기타 정보
Cramer, P.E., et al. 2012. Science Exp.335, 1503.
법적 정보
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
Haihai Dong et al.
Folia neuropathologica, 58(3), 253-264 (2020-10-26)
Traumatic brain injury (TBI) is the leading cause of death and disability around the world in all age groups. The primary injury of TBI is exacerbated by secondary injury, leading to an increased inflammatory response, cell death and even impairment
Che-Feng Chang et al.
Stroke, 51(2), 612-618 (2019-12-13)
Background and Purpose- Enhancement of erythrophagocytosis by macrophages in a timely manner can limit the toxic effects of erythrocyte metabolites and promote brain recovery after intracerebral hemorrhage (ICH). In the current study, we investigated the therapeutic effect of retinoid X
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.